Bendamustine Outperforms R-CHOP in NHL

August 2012
American Health & Drug Benefits;August Special Issue 2012, Vol. 5, p24
Academic Journal
The article discusses a 2012 meeting of the American Society of Clinical Oncology in Chicago, Illinois, focusing on a report from the doctor Mathias J. Rummel concerning the StiL NHL1 clinical trial in which the treatment of non-Hodgkin lymphoma with bendamustine and rituximab was investigated.


Related Articles

  • Intrapericardial and Intrapleural Administration of Rituximab to a Patient with Marginal Zone Lymphoma. Boguradzki, Piotr; Drozd-Sokolowska, Joanna Ewa; Wieczorek, Jolanta; Kowalik, Robert; Starczewska, Marta; Krol, Maria; Kobylecka, Malgorzata; Opolski, Grzegorz; Wiktor-Jedrzejczak, Wiesław // Acta Haematologica;2013, Vol. 130 Issue 3, p169 

    The addition of rituximab to standard chemotherapy has improved the results of the treatment of B cell non-Hodgkin's lymphomas. Under specific circumstances, it can be administered locally, as an alternative to systemic administration. We administered rituximab intrapericardially in an attempt...

  • Phase II study of bendamustine in combination with rituximab as first-line treatment in patients 80 years or older with aggressive B-cell lymphomas. Weidmann, E.; Neumann, A.; Fauth, F.; Atmaca, A.; Al-Batran, S. E.; Pauligk, C.; Jäger, E. // Annals of Oncology;Aug2011, Vol. 22 Issue 8, p1839 

    Background: Rituximab plus combination chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is widely recommended for the treatment of aggressive B-cell lymphomas. However, there is very little information regarding the management of elderly patients.Patients and...

  • The addition of rituximab to CHOP chemotherapy improves overall and failure-free survival for follicular grade 3 lymphoma. M. J. Overman; L. Feng; B. Pro; P. McLaughlin; M. Hess; F. Samaniego; A. Younes; J. E. Romaguera; F. B. Hagemeister; L. Kwak; F. Cabanillas; M. A. Rodriguez; L. E. Fayad // Annals of Oncology;Mar2008, Vol. 19 Issue 3, p553 

    Background: The benefit of adding rituximab to anthracycline-based therapy for follicular lymphoma grade 3 has not been studied. Patients and methods: We retrospectively reviewed the records of 45 patients with follicular grade 3 lymphoma who were treated with rituximab and the combination of...

  • Carboplatin/etoposide.  // Reactions Weekly;11/18/2006, Issue 1128, p8 

    The article presents a case report of female elderly patient who developed non-Hodgkin's lymphoma after receiving carboplatin and etoposide. The patient was diagnosed with adenocarcinoma. After remission, a mass developed on the side of her neck and she began receiving antibacterials. The mass...

  • Improved therapeutic outcomes of DLBCL after introduction of rituximab in Korean patients. Park, Y.; Lee, J.; Ryu, M.; Kim, S.; Kim, D.; Do, Y.; Lee, K.; Oh, S.; Kim, Y.; Suh, C.; Heo, D.; RYoo, B.; Kim, J.; Song, H.; Lee, W.; Kim, H.; Bang, Y.; Yang, S.; Sohn, S.; Kang, Y. // Annals of Hematology;Apr2006, Vol. 85 Issue 4, p257 

    The addition of rituximab to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) has been shown to improve the outcome in all age groups with newly diagnosed diffuse large B-cell lymphoma (DLBCL). We conducted a retrospective analysis to evaluate the impact of this combination...

  • Concomitant statin use does not impair the clinical outcome of patients with diffuse large B cell lymphoma treated with rituximab-CHOP. Samaras, Panagiotis; Heider, Helen; Haile, Sarah R.; Petrausch, Ulf; Schaefer, Niklaus G.; Siciliano, Raffaele Daniele; Meisel, Alexander; Mischo, Axel; Zweifel, Martin; Knuth, Alexander; Stenner-Liewen, Frank; Renner, Christoph // Annals of Hematology;Aug2010, Vol. 89 Issue 8, p783 

    Preclinical data indicated a detrimental effect of statins on the anti-lymphoma activity of rituximab. We evaluated the impact of concomitant statin medication on the response and survival of patients with diffuse large B cell lymphoma (DLBCL) receiving rituximab–cyclophosphamide,...

  • Antineoplastics.  // Reactions Weekly;7/26/2008, Issue 1212, p8 

    A case study involving a 47-year-old man who experienced reactivation of hepatitis C while receiving rituximab, liposomal doxorubicin, cyclophosphamide, vincristine and prednisone for non-Hodgkin's lymphoma is presented. The clinical history of the patient, including his chemotherapy, is...

  • R-CHOP versus R-CVP in the treatment of follicular lymphoma: a meta-analysis and critical appraisal of current literature. Siddhartha, Ganguly; Vijay, Patel // Journal of Hematology & Oncology;2009, Vol. 2, p1 

    Purpose: R-CHOP (rituximab with cyclophosphamide, doxorubicin, vincristine and prednisone) and R-CVP (rituximab with cyclophosphamide, vincristine and prednisone) have both been used successfully in the treatment of patients with symptomatic follicular lymphoma (FL). No study has compared the...

  • Influence of low absolute lymphocyte count of patients with nongerminal center type diffuse large B-cell lymphoma with R-CHOP therapy. Song, M.-K.; Chung, J.-S.; Seol, Y.-M.; Kim, S.-G.; Shin, H.-J.; Choi, Y.-J.; Cho, G.-J.; Shin, D.-H. // Annals of Oncology;Jan2010, Vol. 21 Issue 1, p140 

    Background: Rituximab has dramatic impact on outcome of patients with diffuse large B-cell lymphoma (DLBCL), especially nongerminal center (non-GC) type. A low absolute lymphocyte count (ALC) before rituximab, cyclophosphamide, vincristine, adriamycin, and prednisone (R-CHOP) therapy as a...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics